Receptor News and Research

RSS

ArQule, Daiichi Sankyo initiate enrollment in tivantinib Phase 3 trial for hepatocellular carcinoma

Daiichi Sankyo Company, Limited and ArQule, Inc. today announced that the first patient has been enrolled in the pivotal Phase 3 METIV-HCC (MET-high patients with tivantinib in HCC) trial of tivantinib (ARQ 197).

31 Jan 2013

Northeast Ohio Medical University, CEL-SCI produce new investigational breast cancer vaccine

CEL-SCI Corporation announced that its longstanding collaboration with Northeast Ohio Medical University has produced a new investigational breast cancer vaccine which prevents and treats a HER-2/neu expressing breast cancer tumor in a mouse model of the disease.

31 Jan 2013

Dual renin angiotensin system blockade: too many cons

Any benefit of dual blockade of the renin angiotensin system is limited to its effects on surrogate endpoints, and outweighed by an excessive risk for adverse events such as hypotension, hyperkalemia, and renal failure, argue hypertension experts.

31 Jan 2013

Acute schizophrenia shows increased NMDA-R antibody prevalence

Patients with acute schizophrenia have an increased prevalence of N-methyl-D-aspartate glutamate receptor antibodies that is distinct from that seen in NMDA-R encephalitis, scientists have found.

31 Jan 2013

Being married and cohabiting reduces risk of heart attack in both men and women in all age groups

A large population-based study from Finland has shown that being unmarried increases the risk of fatal and non-fatal heart attack in both men and women whatever their age. Conversely, say the study investigators, especially among middle-aged couples, being married and cohabiting are associated with "considerably better prognosis of acute cardiac events both before hospitalization and after reaching the hospital alive".

31 Jan 2013

Binge drinking causes insulin resistance and increases risk of Type 2 diabetes

Binge drinking causes insulin resistance, which increases the risk of Type 2 diabetes, according to the results of an animal study led by researchers at the Diabetes Obesity and Metabolism Institute at the Icahn School of Medicine at Mount Sinai.

31 Jan 2013

Erbin protein critical to brain excitement

Scientists have found an early step in how the brain's inhibitory cells get excited. A natural balance of excitement and inhibition keeps the brain from firing electrical impulses randomly and excessively, resulting in problems such as schizophrenia and seizures. However excitement is required to put on the brakes.

31 Jan 2013

Androgens could constitute an efficient treatment against multiple sclerosis

Testosterone and its derivatives could constitute an efficient treatment against myelin diseases such as multiple sclerosis, reveals a study by researchers from the Laboratoire d'Imagerie et de Neurosciences Cognitives, in collaboration in particular with the "Neuroprotection et Neurorégénération: Molécules Neuroactives de Petite Taille" unit.

30 Jan 2013

Clarient adopts QIAGEN’s therascreen KRAS test to diagnose colorectal cancer

QIAGEN N.V. today announced that Clarient - a GE Healthcare Company and leading provider of cancer laboratory testing services in the United States - has adopted the use of the therascreen KRAS RGQ PCR Kit (therascreen KRAS test) as a companion diagnostic to guide the use of Erbitux (cetuximab) as a treatment in patients with metastatic colorectal cancer.

From QIAGEN Manchester Limited 30 Jan 2013

NRC, AvidBiologics partner to develop three novel ADCs for treatment of cancer

AvidBiologics Inc., a life sciences company developing antibody-drug conjugates (ADCs), announces the conclusion of an agreement with the National Research Council Canada (NRC) to develop three novel ADCs for the treatment of cancer.

30 Jan 2013

Dectin-1 potential target for nasal polyposis

The transmembrane protein Dectin-1 appears to play a role in the pathogenesis of nasal polyposis, providing a potential new target for treating the condition, report Chinese researchers.

29 Jan 2013

Five genes hold key to meningioma make up

Research published in Science shows that mutations in five genes characterize most meningiomas.

28 Jan 2013

HSS involving resiniferatoxin receives U.S. patent to alleviate intractable pain

The U. S. Patent and Trademark Office recently issued a patent to the U. S. Department of Health and Human Services involving resiniferatoxin, or RTX, an experimental compound that represents a potential new class of drugs to alleviate the intractable pain that can occur in people with advanced cancer, severe arthritis, and other extremely chronic conditions.

28 Jan 2013

HDL cholesterol key to fighting lymphoma

High-density lipoprotein cholesterol could provide a novel treatment target for patients with lymphoma, US scientists believe.

25 Jan 2013

Keeping active can slow down memory loss in Alzheimer's patients

Keeping active can slow down the progression of memory loss in people with Alzheimer's disease, a study has shown.

25 Jan 2013

Biomedical engineers identify natural switch that controls breast cancer metastasis

With a desire to inhibit metastasis, Cornell biomedical engineers have found the natural switch between the body's inflammatory response and how malignant breast cancer cells use the bloodstream to spread.

24 Jan 2013

Study identifies how astrocytes regulate a neurotransmitter involved in sleep

Neuroscience researchers from Tufts University have found that our star-shaped brain cells, called astrocytes, may be responsible for the rapid improvement in mood in depressed patients after acute sleep deprivation. This in vivo study, published in the current issue of Translational Psychiatry, identified how astrocytes regulate a neurotransmitter involved in sleep.

23 Jan 2013

New apatamer can boost therapeutic effect of cell-based vaccines

A small compound called an aptamer that specifically targets and stimulates a human immune cell can greatly increase the effectiveness of an immunotherapeutic drug designed to destroy malignant or virus-infected cells. The development of a novel apatamer that recognizes activated T-lymphocytes and can boost the therapeutic effect of cell-based vaccines is described in an article in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc. publishers.

23 Jan 2013

Novel way to engineer specialized immune cells targeted by the AIDS virus

Researchers at the Stanford University School of Medicine have found a novel way to engineer key cells of the immune system so they remain resistant to infection with HIV, the virus that causes AIDS.

23 Jan 2013

UB scientists propose first genomic explanation for schizophrenia

New University at Buffalo research demonstrates how defects in an important neurological pathway in early development may be responsible for the onset of schizophrenia later in life.

23 Jan 2013